Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials.
about
Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control studyImmunogenicity and cross-reactivity of 2009-2010 inactivated seasonal influenza vaccine in US adults and elderlyPredictors of acceptance of H1N1 influenza vaccination by FDNY firefighters and EMS workersVaccines for preventing influenza in healthy adultsReduced antibody responses to the pandemic (H1N1) 2009 vaccine after recent seasonal influenza vaccinationAssaying the Potency of Influenza VaccinesInfluenza virus vaccines: lessons from the 2009 H1N1 pandemicPrevalence of 2009 pandemic influenza A (H1N1) virus antibodies, Tampa Bay Florida--November-December, 2009Effectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 U.S. communitiesSeroprevalence of pandemic H1N1 antibody among health care workers in Hong Kong following receipt of monovalent 2009 H1N1 influenza vaccineImmunogenicity and reactogenicity of 2009 influenza A (H1N1) inactivated monovalent non-adjuvanted vaccine in elderly and immunocompromised patientsSafety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre studyA Single Dose of an Avian H3N8 Influenza Virus Vaccine Is Highly Immunogenic and Efficacious against a Recently Emerged Seal Influenza Virus in Mice and FerretsPhase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009.The 2009 influenza A (H1N1) pandemic: what have we learned in the past 6 months.Seroconversion of 2009 pandemic influenza A (H1N1) vaccination in kidney transplant patients and the influence of different risk factors.Antibody response to influenza A(H1N1)pdm09 among healthcare personnel receiving trivalent inactivated vaccine: effect of prior monovalent inactivated vaccine.The long-term immunogenicity of an inactivated split-virion 2009 pandemic influenza A H1N1 vaccine: Randomized, observer-masked, single-center clinical study.The pandemic influenza A (H1N1) 2009 vaccine does not increase the mortality rate of idiopathic interstitial pneumonia: a matched case-control study.Responses to A(H1N1)pdm09 influenza vaccines in participants previously vaccinated with seasonal influenza vaccine: a randomized, observer-blind, controlled study.Clinical and immune responses to inactivated influenza A(H1N1)pdm09 vaccine in children.AS03B-adjuvanted H5N1 influenza vaccine in children 6 months through 17 years of age: a phase 2/3 randomized, placebo-controlled, observer-blinded trial.Long-term immunogenicity of an inactivated split-virion 2009 pandemic influenza A H1N1 virus vaccine with or without aluminum adjuvant in miceImmunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for childrenSafety and immunogenicity of influenza whole inactivated virus vaccines: A phase I randomized clinical trial.Phase 1 study of pandemic H1 DNA vaccine in healthy adultsCommunity awareness, use and preference for pandemic influenza vaccines in Pune, IndiaDetermination of serum antibodies against swine-origin influenza A virus H1N1/09 by immunofluorescence, haemagglutination inhibition, and by neutralization tests: how is the prevalence rate of protecting antibodies in humans?A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models.Safety and immunogenicity of influenza A H1N1 vaccines.Detection of extensive cross-neutralization between pandemic and seasonal A/H1N1 Influenza Viruses using a pseudotype neutralization assayRepeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised hostOptimizing vaccine allocation at different points in time during an epidemic.Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine.Vaccination of patients with mild and severe asthma with a 2009 pandemic H1N1 influenza virus vaccine.Panvax(®): a monovalent inactivated unadjuvanted vaccine against pandemic influenza A (H1N1) 2009.Inactivated influenza vaccines: recent progress and implications for the elderly.Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination.Antibody dynamics of 2009 influenza A (H1N1) virus in infected patients and vaccinated people in China.Durability of antibody responses after receipt of the monovalent 2009 pandemic influenza A (H1N1) vaccine among HIV-infected and HIV-uninfected adults.
P2860
Q21144621-4221EBEB-5416-4B78-BF3C-06E2F4D63378Q21560857-00346023-BCA4-41F7-98A1-E43113A99CEAQ23918433-DAAB9A5B-B152-44D2-9CF5-9B736BB83A4DQ24197955-5EA2A619-FEE6-4513-B579-648A0D0F7983Q24607378-DC39FB00-C292-4804-A322-A59597399871Q26783499-A4753910-38F3-46E9-BB11-2A644B8D0C99Q27027029-27176BB0-29C6-4822-BB1A-B13679968521Q28741061-10C8A6E7-CF6D-49A0-BEAC-740730B7B13FQ28741469-8DDDECF4-5EA2-4D1A-902F-8D6B6741A339Q28742920-D018B2D7-6E0C-4DAE-BAA1-F69B07868794Q28743021-A67BE839-A769-4C32-9752-54AB65031A6BQ28751886-83C954EA-2454-4B79-A838-0A75439B464AQ30204020-B1B51180-FD43-4CEF-BAEB-30758B1D55E7Q30224646-170BC846-5771-48C6-BC54-4219A99E95DCQ30227033-8AA8707E-7574-4D3F-B43A-F1D6917ABBB4Q30354634-FF7427B2-A453-4E0F-84E0-540710F8C2C8Q30357144-BFB27717-7917-4218-9422-C93593E3C001Q30357303-D7192A2B-3E55-444C-867B-311715E75C72Q30359671-561A1C52-61CB-4F43-A8F3-EA9912E61773Q30362883-0B06340B-F4BA-4CF7-B8E5-657A72D2795DQ30366806-6E315FE2-6B00-42A0-8966-79516BF11A65Q30367603-570CDF76-F8CC-4DDF-9DC3-433D617FF2A6Q30370790-9FAE65E8-8533-486D-8D92-B279D877A630Q30371111-6365D013-F731-4B4B-A792-F56B48898B4DQ30372521-29418308-0850-4BBA-8A68-9CB7A5FAF018Q30373824-E19CE38D-87B4-47A9-B759-1583883505BCQ30376060-FC732CE0-7EDF-4B3D-A02E-6921F07F33FBQ30385755-62673C50-C772-4E7E-AC2C-8792BB86A764Q30386068-AEAEA9AC-BA41-40D3-ADBC-37C043068125Q30387728-C07E5EF2-14A4-4967-8B1D-E935BF88A50FQ30390290-2EEA70E4-F04B-4D98-8FA3-B7AE39F6CA3EQ30395200-5DE3035B-9271-49CE-8F82-61B95C188019Q30396382-93D2E877-4BD0-4DBD-B9A5-1A4970E104B0Q30396654-CC93F0B6-2DF9-4D94-89F0-C8A3AD89AD32Q30397219-1FFE1ECD-D05E-49CB-BE9C-00638B6FE366Q30397513-B4B2FF85-0B20-448F-A448-DDE31ADE37A6Q30399057-4A9D940F-3464-44FE-BA86-04A93C7FA503Q30399474-88688789-985B-400E-A733-F85082C22189Q30400114-0EEF557E-DCBF-403A-8E08-F8671EFEDABDQ30400385-2608620F-9975-4DC7-8C18-F9F911168341
P2860
Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Immune response after a single ...... sed controlled phase 2 trials.
@ast
Immune response after a single ...... sed controlled phase 2 trials.
@en
type
label
Immune response after a single ...... sed controlled phase 2 trials.
@ast
Immune response after a single ...... sed controlled phase 2 trials.
@en
prefLabel
Immune response after a single ...... sed controlled phase 2 trials.
@ast
Immune response after a single ...... sed controlled phase 2 trials.
@en
P2093
P1433
P1476
Immune response after a single ...... ised controlled phase 2 trials
@en
P2093
Eric Plennevaux
Mark Blatter
Martine Denis
Mary-Kate Reeves-Hoché
P356
10.1016/S0140-6736(09)62026-2
P407
P50
P577
2009-12-15T00:00:00Z